Related Experiment Videos
Recombinant uteroglobin prevents the experimental crescentic glomerulonephritis
Dong-Sup Lee1, Seung Hee Yang, Hyun Lee Kim
1Cancer Research Institute, Department of Anatomy, Seoul National University College of Medicine, Seoul, Korea.
Kidney International
|August 26, 2004
Summary
Recombinant uteroglobin prevents crescentic glomerulonephritis in mice by reducing proteinuria and inhibiting antibody and complement deposition. This suggests uteroglobin
Area of Science:
- Immunology
- Nephrology
- Molecular Biology
Background:
- Uteroglobin possesses known immunomodulatory properties.
- Its therapeutic potential in glomerulonephritis remains uncertain.
- This study investigates uteroglobin's effect on experimental crescentic glomerulonephritis.
Purpose of the Study:
- To evaluate the preventive effects of recombinant uteroglobin on anti-GBM antibody-induced glomerulonephritis.
- To assess the impact of uteroglobin on renal injury markers and histological changes.
- To explore the underlying mechanisms of uteroglobin's action.
Main Methods:
- Experimental crescentic glomerulonephritis induced by anti-GBM antibodies in mice.
- Treatment with recombinant uteroglobin or PBS post-induction.
- Evaluation of proteinuria, serum creatinine, and renal histology at 7, 14, and 21 days.
- In vitro mesangial cell proliferation assays.
Main Results:
- Recombinant uteroglobin significantly reduced proteinuria and attenuated histological signs of glomerulonephritis.
- It inhibited antibody and complement-3 deposition in glomeruli.
- In vitro, uteroglobin dose-dependently blunted mesangial cell proliferation.
Conclusions:
- Recombinant uteroglobin demonstrates preventive effects in experimental crescentic glomerulonephritis.
- Uteroglobin shows therapeutic potential for human chronic glomerulonephritis.